Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection
dc.creator | Dalekos, G. N. | en |
dc.creator | Obermayer-Straub, P. | en |
dc.creator | Bartels, M. | en |
dc.creator | Maeda, T. | en |
dc.creator | Kayser, A. | en |
dc.creator | Braun, S. | en |
dc.creator | Loges, S. | en |
dc.creator | Schmidt, E. | en |
dc.creator | Gershwin, M. E. | en |
dc.creator | Manns, M. P. | en |
dc.date.accessioned | 2015-11-23T10:25:02Z | |
dc.date.available | 2015-11-23T10:25:02Z | |
dc.date.issued | 2003 | |
dc.identifier | 10.1016/s0168-8278(03)00356-8 | |
dc.identifier.issn | 0168-8278 | |
dc.identifier.uri | http://hdl.handle.net/11615/26847 | |
dc.description.abstract | Background/Aims: Cytochromes P4502A6 (CYP2A6) and P4501A2 (CYP1A2) were described as hepatic autoantigens in the autoimmune polyglandular syndrome type-1 (APS-1). We evaluated the significance of anti-CYP2A6 and anti-CYP1A2 in several hepatic diseases in the absence of APS-1. Methods: A radioligand assay (RLA) based on immunoprecipitation of [S-35]-methionine-labeled CYP2A6 and CYP1A2 was used. Four hundred and thirty subjects with chronic viral hepatitis (n = 185), autoimmune liver diseases (n = 181), autoimmune rheumatic diseases (ARD, n = 31) and healthy (n = 33) were tested. Results: Seven out of 366 patients with liver diseases were anti-CYP2A6 positive. Neither healthy nor ARD patients showed anti-CYP2A6. One out of 181 patients with autoimmune liver diseases tested anti-CYP2A6 positive. A significantly higher prevalence of anti-CYP2A6 (P < 0.05) was detected with six out of seven patients positive in the viral hepatitis group. The latter were infected by flaviviruses (1 HGV/GBVC, 5 HCV). 4/5 HCV/anti-CYP2A6 positive sera were positive for anti-LKM-1 by immunofluorescence and for anti-CYP2D6 by RLA. None of the 430 sera recognized CYP1A2. Conclusions: For the first time CYP2A6 is reported as a hepatic autoantigen in patients with viral hepatitis caused by flaviviruses and in particular in HCV/anti-LKM-1 positive patients. Multicenter studies are needed in order to investigate the clinical importance of this novel finding. This study further supports that anti-CYP2A6 in the absence of flavivirus is rather limited to APS-1. (C) 2003 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. | en |
dc.source.uri | <Go to ISI>://WOS:000186441500019 | |
dc.subject | autoimmune hepatitis | en |
dc.subject | autoimmunity | en |
dc.subject | chronic hepatitis | en |
dc.subject | cytochrome P450 | en |
dc.subject | 2A6 | en |
dc.subject | cytochrome P450 1A2 | en |
dc.subject | cytochrome P450 2D6 | en |
dc.subject | hepatitis C virus | en |
dc.subject | LKM | en |
dc.subject | antibody | en |
dc.subject | KIDNEY MICROSOMAL AUTOANTIBODIES | en |
dc.subject | POLYGLANDULAR SYNDROME TYPE-1 | en |
dc.subject | AUTOIMMUNE LIVER-DISEASE | en |
dc.subject | CHRONIC ACTIVE HEPATITIS | en |
dc.subject | RADIOLIGAND ASSAY | en |
dc.subject | ANTIBODIES | en |
dc.subject | P4502D6 | en |
dc.subject | IDENTIFICATION | en |
dc.subject | HETEROGENEITY | en |
dc.subject | P450IID6 | en |
dc.subject | Gastroenterology & Hepatology | en |
dc.title | Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection | en |
dc.type | journalArticle | en |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |